Fragmin (dalteparin sodium injection)

Published Online: Tuesday, November 1, 2005

Eisai Inc (Teaneck, NJ) recently announced an in-license agreement with Pfizer Inc for exclusive US rights to promote Fragmin. The company will also assume responsibility for postmarketing studies and product distribution, as well as book all US sales. Fragmin is a clot-preventing agent, for subcutaneous injection only, in a class of drugs known as low-molecular-weight heparins. In the United States, Fragmin is indicated for prevention of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing hip replacement surgery, in at-risk patients undergoing abdominal surgery, or in at-risk acutely ill patients whose mobility is severely restricted. The product is also approved for prophylaxis of ischemic complications resulting from unstable angina and non-Q-wave myocardial infarction, when used with aspirin. For more information, visit

Latest Articles
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
As a result of implementation difficulties, the FDA announced that it will extend the pharmacy certification deadline for the clozapine risk evaluation and mitigation strategy program.
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Latest Issues